Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
105P - Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Toxicity profile antibody-drug conjugates (ADCs) in metastatic breast cancer patients: A systematic review and meta-analysis based on studies’ design
Presenter: Silvia Belloni
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Receptor change on residual disease following neoadjuvant therapies for locally advanced breast cancer fails to impact oncological and survival outcomes
Presenter: Rionagh Lynch
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Presenter: Davide Ciardiello
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - Impact of tissue factor on clinical and biological characteristics in patients with advanced pancreatic cancer
Presenter: Taro Shibuki
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Multiomic profiling based on <italic>Akkermansia muciniphila</italic> in advanced non-small cell lung cancer
Presenter: Lorenzo Belluomini
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Transforming public patient omic data into precision oncology targets: A comprehensive pan-cancer approach
Presenter: Eléonore Fox
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Whole transcriptome sequencing of lung tissue to combine disease classification and identification of actionable targets
Presenter: Alejandro Pallares Robles
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - Genetic profiling of breast cancer in a developing country: Towards the establishment of oncogenetics in Cameroon
Presenter: Kenn Chi Ndi
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Uncovering the prognostic potential of FGFR2c isoform expression in advanced gastroesophageal cancer through MONSTAR-SCREEN-2 analysis
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract